223 related articles for article (PubMed ID: 2123635)
21. Apolipoprotein and lipid abnormalities in uremic children on hemodialysis.
Ohta T; Matsuda I
Clin Chim Acta; 1985 Apr; 147(2):145-54. PubMed ID: 3921292
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis.
Babazono T; Miyamae M; Tomonaga O; Omori Y
Adv Perit Dial; 1996; 12():120-5. PubMed ID: 8865885
[TBL] [Abstract][Full Text] [Related]
23. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis.
Attman PO; Alaupovic P
Nephron; 1991; 57(4):401-10. PubMed ID: 2046821
[TBL] [Abstract][Full Text] [Related]
24. Apo AIV in plasma and dialysate fluid of CAPD patients: comparison with other apolipoproteins.
Kandoussi A; Cachera C; Reade R; Pagniez D; Fruchart JC; Tacquet A
Nephrol Dial Transplant; 1992; 7(10):1026-9. PubMed ID: 1331878
[TBL] [Abstract][Full Text] [Related]
25. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Fytili CI; Progia EG; Panagoutsos SA; Thodis ED; Passadakis PS; Sombolos KI; Vargemezis VA
Ren Fail; 2002 Sep; 24(5):623-30. PubMed ID: 12380908
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of lipid parameters and bioindices in patients with different stages of chronic renal failure.
Cabarkapa V; Djerić M; Stosić Z; Sakac V; Zagorka LC; Vucković B
Vojnosanit Pregl; 2012 Nov; 69(11):961-6. PubMed ID: 23311247
[TBL] [Abstract][Full Text] [Related]
27. Residual renal function affects lipid profile in patients undergoing continuous ambulatory peritoneal dialysis.
Kagan A; Elimalech E; Lemer Z; Fink A; Bar-Khayim Y
Perit Dial Int; 1997; 17(3):243-9. PubMed ID: 9237284
[TBL] [Abstract][Full Text] [Related]
28. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
[TBL] [Abstract][Full Text] [Related]
29. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
[TBL] [Abstract][Full Text] [Related]
30. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
[TBL] [Abstract][Full Text] [Related]
31. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.
Dieplinger H; Schoenfeld PY; Fielding CJ
J Clin Invest; 1986 Apr; 77(4):1071-83. PubMed ID: 3082933
[TBL] [Abstract][Full Text] [Related]
32. Comparison of lipid abnormalities in continuous ambulatory peritoneal dialysis and hemodialysis patients.
Ong-Ajyooth L; Sirisalee K; Shayakul C; Vareesangthip K; Vasuvattakul S; Vanichakarn S; Nimmannit S; Chirawong P; Ong-Ajyooth S; Nilwarangkur S
Transplant Proc; 1994 Aug; 26(4):2077-9. PubMed ID: 8066677
[No Abstract] [Full Text] [Related]
33. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
34. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
Misra M; Webb AT; Reaveley DA; Doherty E; O'Donnell M; Seed M; Brown EA
Adv Perit Dial; 1997; 13():168-73. PubMed ID: 9360675
[TBL] [Abstract][Full Text] [Related]
35. Observed relationship between ratios HDL-cholesterol/total cholesterol and apolipoprotein A1/apolipoprotein B.
Kuyl JM; Mendelsohn D
Clin Biochem; 1992 Oct; 25(5):313-6. PubMed ID: 1490290
[TBL] [Abstract][Full Text] [Related]
36. Lipids in diabetic and nondiabetic hemodialysis and CAPD patients.
Avram MM; Antignani A; Goldwasser P; Lustig A; Fein PA; Mushnick R; Quinones E; Rao Y; Mittman N
ASAIO Trans; 1988; 34(3):314-6. PubMed ID: 3196527
[TBL] [Abstract][Full Text] [Related]
37. [The atherogenic aspect of the lipoprotein composition in hemodialysis patients].
Viener A; Aviram M; Brook JG
Harefuah; 1986 Mar; 110(5):217-9. PubMed ID: 3087842
[No Abstract] [Full Text] [Related]
38. Serum lipids and apolipoproteins A-I, A-II, and B in hyperthyroidism before and after treatment.
Muls E; Blaton V; Rosseneu M; Lesaffre E; Lamberigts G; De Moor P
J Clin Endocrinol Metab; 1982 Sep; 55(3):459-64. PubMed ID: 6808006
[TBL] [Abstract][Full Text] [Related]
39. Influence of haemodialysis on high-sensitivity C-reactive protein, lipoprotein(a), apolipoproteins A and B.
Lippi G; Tessitore N; Salvagno GL; Bedogna V; Bassi A; Montagnana M; Lupo A; Guidi GC
Clin Biochem; 2007 Nov; 40(16-17):1336-8. PubMed ID: 17826754
[TBL] [Abstract][Full Text] [Related]
40. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease.
Kim SB; Yang WS; Kang ES; Min WK; Park JS
Perit Dial Int; 1997; 17(3):236-42. PubMed ID: 9237283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
